|Application ||WB, IF, E|
|Other Accession||P02647, 113992|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||30778 Da|
|Application Notes||ApoA1 antibody can be used for detection of ApoA1 by Western blot at 1 µg/mL. Antibody can also be used for immunoflourescence starting at 20 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||ApoA1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||ApoA1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.|
|Tissue Location||Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ApoA1 Antibody: Apolipoprotein A1 (ApoA1) is the major protein component of high density lipoprotein (HDL) in plasma. ApoA1 is synthesized in the liver and small intestine and promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT), the enzyme responsible for the formation of most plasma cholesteryl esters. Defects in ApoA1 are associated with HDL deficiency, Tangier disease, and systemic non-neuropathic amyloidosis.
Sorci-Thomas MG, Prack MM, Dashti N, et al. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. J. Lipid Res.1989; 30:1397-403.
Lai C-Q, Parnell LD, and Ordovas JM. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr. Opin. Lipid.2005; 16:153-66.
If you have any additional inquiries please email technical services at email@example.com.